日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

ATR抑制剂ceralasertib通过调节肿瘤微环境增强癌症检查点免疫疗法的疗效。

Elizabeth L Hardaker # ,Emilio Sanseviero # ,Ankur Karmokar # ,Devon Taylor # ,Marta Milo ,Chrysis Michaloglou ,Adina Hughes ,Mimi Mai ,Matthew King ,Anisha Solanki ,Lukasz Magiera ,Ricardo Miragaia ,Gozde Kar ,Nathan Standifer ,Michael Surace ,Shaan Gill ,Alison Peter ,Sara Talbot ,Sehmus Tohumeken ,Henderson Fryer ,Ali Mostafa ,Kathy Mulgrew ,Carolyn Lam ,Scott Hoffmann ,Daniel Sutton ,Larissa Carnevalli ,Fernando J Calero-Nieto ,Gemma N Jones ,Andrew J Pierce ,Zena Wilson ,David Campbell ,Lynet Nyoni ,Carla P Martins ,Tamara Baker ,Gilberto Serrano de Almeida ,Zainab Ramlaoui ,Abdel Bidar ,Benjamin Phillips ,Joseph Boland ,Sonia Iyer ,J Carl Barrett ,Arsene-Bienvenu Loembé ,Serge Y Fuchs ,Umamaheswar Duvvuri ,Pei-Jen Lou ,Melonie A Nance ,Carlos Alberto Gomez Roca ,Elaine Cadogan ,Susan E Critichlow ,Steven Fawell ,Mark Cobbold ,Emma Dean ,Viia Valge-Archer ,Alan Lau ,Dmitry I Gabrilovich ,Simon T Barry

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

PARP1 选择性抑制剂 saruparib (AZD5305) 在患者来源的 BRCA1/2 相关癌症模型中表现出强效且持久的抗肿瘤活性

Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J Arenas, Helena Verdaguer, Fernando J Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

在纺锤体组装检查点被 AURKB 或 TTK 抑制剂消除后,BID 表达决定了癌细胞的凋亡命运

Jordi Bertran-Alamillo, Ana Giménez-Capitán #, Ruth Román #, Sara Talbot #, Rebecca Whiteley #, Nicolas Floc'h, Elizabeth Martínez-Pérez, Matthew J Martin, Paul D Smith, Ivana Sullivan, Mikkel G Terp, Jamal Saeh, Cristina Marino-Buslje, Giulia Fabbri, Grace Guo, Man Xu, Cristian Tornador, Andrés Agu

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

AKT 抑制剂 capivasertib 与 SERD 氟维司群联合使用对 palbociclib 耐药的 ER+ 乳腺癌临床前模型有效

Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S W

Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models

ATM 状态与患者来源的异种移植模型中 DNA 损伤反应抑制剂敏感性的关系

Ankur Karmokar, Rebecca Sargeant, Adina M Hughes, Hana Baakza, Zena Wilson, Sara Talbot, Sarah Bloomfield, Elisabetta Leo, Gemma N Jones, Maria Likhatcheva, Luis Tobalina, Emma Dean, Elaine B Cadogan, Alan Lau

Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, Canada

加拿大魁北克省一项检测阴性设计研究显示,单剂量信使RNA疫苗对医护人员预防严重急性呼吸综合征冠状病毒2感染的有效性,在接种后16周内持续存在。

Carazo, Sara; Talbot, Denis; Boulianne, Nicole; Brisson, Marc; Gilca, Rodica; Deceuninck, Geneviève; Brousseau, Nicholas; Drolet, Mélanie; Ouakki, Manale; Sauvageau, Chantal; Barkati, Sapha; Fortin, Élise; Carignan, Alex; De Wals, Philippe; Skowronski, Danuta M; De Serres, Gaston